Hyaluronan (hyaluronic acid) is a naturally occurring polysaccharide of a linear repeating disaccharide unit consisting of β-(1→4)-linked D-glucopyranuronic acid and β-(1→3)-linked 2-acetamido-2-deoxy-D-glucopyranose, which is present in extracellular matrices, the synovial fluid of joints, and scaffolding that comprises cartilage.
Despite its simplistic structure hyaluronan behaves quite differently from other glycosaminoglycans in its mechanism of synthesis, its size, and its physico-chemical properties. The network-forming, viscoelastic and its charge characteristics are important to many biochemical properties of living tissues. It is an important pericellular and cell surface constituent which, through interaction with other macromolecules such as proteins, participates in regulating cell behavior during numerous morphogenic, restorative and pathological processes in the body. The knowledge of such biological functions of hyaluronan has led to the preparation of biomaterials for surgical implants and drug conjugates for targeted delivery.
The interest in the role of hyaluronan diseases such as various forms of cancers, arthritis and osteoporosis has led to new impetus in research and development. Our laboratory has been involved in the study of chemistry and physico-chemical properties of hyaluronan with a view to develop biomaterials and drugs conjugates.
As a general arrangement of the review the subject is divided into: biological function and synthesis in nature; industrial production of hyaluronan; chemical modification of hyaluronan; and market position of hyaluronan.
Biological function and synthesis in nature
Hyaluronan was first isolated from the vitreous body of the eye by Mayer and Palmer [1] and then found in all vertebrates tissues, from skin to synovial fluid between joins, from umbilical cord to skin and cartilage [2] [3] [4] [5] [6] [7] [8] [9] .
Hyaluronan is a glycosaminoglycan that has a number of biological functions in vertebrates, being essential for tissue and organ integrity and function. Hyaluronan molecules are involved in the activation of signaling
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The primary structural function of HA is related to its viscoelastic and hygroscopic properties. It acts as shockadsorber and offers lubrication to the joints, creates a protective and flexible layer between tissues, influence cell responses during a number of processes, inflammation and cancer [21] [22] [23] [24] [25] [26] [27] [28] . A wide range of different cell responses are evoked by HA molecules which different molecular weights [29] . In general, high molecular weight hyaluronan inhibits cell differentiation and promotes cell proliferation, being involved in tissue regeneration, wound healing, epithelial integrity and embryogenesis. Lower molecular weights HA are anti-angiogenic, immunosuppressive and hamper the differentiation by limiting the cell-cell interactions or ligand access to cell receptors. Finally, HA oligomers showed angiogenic and proinflammatory activity, increase immune response and are capable to slow down growth of a number of tumors in vivo [30] [31] [32] [33] [34] [35] [36] [37] .
HA mediates his biological function through specific protein receptors present on the different cell surface, which include CD44, HARE, RHAMM, LYVE [29, [38] [39] [40] [41] [42] [43] .
In nature, hyaluronan is synthesized by specific glycosyltransferases (HA synthases or HAse) that polymerizes the activated donor uridine diphospho-sugars UDP-glucuronic acid and UDP-N-acetyl-glucosamine into hyaluronan [44] [45] [46] [47] . In nature, hyaluronan was shown to be synthesized also by a small number of microbial pathogens such us Pasteurella multocida and the Lancefield group A and C streptococci among which Streptococcus equi, the human pathogen Streptococcus pyogenes and the bovine pathogen Streptococcus uberis. [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . These microorganisms adopted the strategy to encapsulate their cells with hyaluronan in order to perfectly disguise from the host animal defense system and allow the adhesion and colonization. In Streptococcus and Pasteurella, the HA capsules represent virulence factors affording to the bacteria a stealth function against the recognition from the host immune system [45, [59] [60] [61] . On the contrary to other bacterial capsule polysaccharides triggering the antibody immune response, HA is not immunogenic because it is a normal component of the host body conferring to these pathogen bacteria an efficient molecular camouflage. Moreover, the HA capsule provide a protection against the reactive oxides released by leukocytes [62] and facilitate the bacteria migration through epithelial layer into tissues [63] .
In Streptococcus equi subsp. zooepidemicus hyaluronic acid capsular material contributes to adherence properties of the pathogen possibly conferring to the bacteria the resistance to phagocytosis by macrophages [64] [65] [66] .
The importance of the capsule in pharyngeal colonization and other inflammatory syndromes caused by Streptococcus pyogenes may reflect the role of hyaluronan as a specific ligand for attachment of Streptococcus pyogenes to the hyaluronan-binding protein CD44 on pharyngeal epithelial cells [67, 68] .
Pasteurella multocida, a prevalent animal pathogen, employs a hyaluronan polysaccharide capsule to avoid host defenses. This pathogen is associated with various diseases in many animal species; a number of studies suggested that there is a correlation between the capsule and the virulence of P. multocida, for example in the pathogenesis of fowl cholera [52, [69] [70] [71] [72] [73] [74] .
This biomimetic strategy of prokaryotic organisms efficiently exploits the chemical identity of the bacterial capsular HA molecules to that of the eukaryotic host extracellular matrix. Such a biomimetic strategy adopted by specialized prokaryotic cells to proliferate into an animal host organism has the same goal as many types of endogenous cells like tumor cells to invade and proliferate into normal tissues. In fact, a large number of tumor cells over express membrane receptors for hyaluronan in order to more efficiently interact with this major component of the extracellular matrix to easily spread and proliferate into the tissues [75, 76] .
The existence of hyaluronan outside the animals and their pathogens has been demonstrated in green microalgae infected by specialized viruses. Chlorovirus is a group of virus of Phycodnaviridae family that infects the eukaryotic microalgae Chlorella [77, 78] . Chlorovirus dsDNA genome unusually encodes enzymes involved in sugar metabolism. The 330-kilobase genome of the chlorovirus PBCV-1 encode other than fructose-6-phosfate aminotransferase and UDP-glucose dehydrogenase also a HA synthase, resulting in the production of an HA capsule surrounding the Chlorella infected cells. However, some chlorovirus contain both HA synthase and chitin synthase genes and form both hyaluronan and chitin, an N-acetyl-glucosamine based polysaccharide found in the crustaceans shell, in the insect exoskeletons and fungi cell wall [79] , on the surface of their infected cells [80] [81] [82] .
The function of a HA capsule in chlorovirus infected chlorella cells is still unknown; however, since the genes encoding for HA synthesis are transcribed early in PBCV-1 infection and HA accumulates on the external surface of the infected chlorella cells, hyaluronan synthesis might be related to the virus life cycle and the recognition of infected cells. The distribution of hyaluronan synthases from vertebrates to bacterial pathogens and algal viruses makes these fascinating glycosyltransferases an interesting evolutionary case which can advance the knowledge on the biological functions of a typical natural molecule like hyaluronan.
Industrial production of hyaluronan
HA has been traditionally produced by extracting from rooster combs and bovine vitreous humor The process is difficult, particularly to ensure the biological safety and to control the molecular weight of the product [3] . Hence, since 1980's, the commercial production of HA has moved to the fermentation process using streptococcal bacteria. The most used strains are S. equi subsp. equi and S. equi subsp. zooepidemicus that naturally achieve good HA production rate.
Improved HA producer streptococcal strain has been obtained by random mutagenesis followed by a serial selection of the mutant clones. The aim of the strain selection was mainly oriented to the reduction of the HAdepolymerising enzyme (hyaluronidase-negative strains) and other extracellular proteins such as the virulence factor streptolysins, the exotoxins responsible for the β-hemolysis (non-hemolytic strains) [83] as well as the production of high molecular weight HA [84, 85] . Several studies were performed in order to improve the HA yield, molecular weight and reduce the polydispersity by an accurate control of the growing conditions. Unfortunately, Streptococci are lactic acid bacteria that demand expensive complex growth medium containing yeast or animal extract, peptone and serum supplemented with an high glucose content [83, 86, 87] .
The HA biosynthesis require a large amount of energy and compete with the cell growth because of the large pathways overlapping with the cell wall biosynthesis ( Figure 1 ). Indeed, when unlimited resource are available, the optimal growth conditions is observed at 37°C and around pH 7 while, the highest HA productivity and molecular weight is observed at suboptimal growing conditions. Limiting the resources available, in particular glucose, first occurs a decline in HA productivity followed by the HA molecular weight [55] . Streptococci are facultative anaerobes incapable to oxidative phosphorylation however, aerobic culturing condition it is known to greatly improve the HA production. These effects are probably the results of improved energy efficiency when the NADH oxidase (NOX) removes the excess of NADH in presence of oxygen [88] . Metabolically engineered Streptococcus strain with an increased NOX activity resulted in 33% improvement of ATP yield leading to a 15% improvement in biomass. Unfortunately, any HA yield or molecular weight improvement was not observed [89] .
Even under the best conditions, and the use of continuous cultivation, the HA yield does not exceed the practical limit of 5-10 g/L. Further improvement requires genetic engineering of the producer microorganism. Partial or complete genome sequence of the most relevant HA producing microorganisms is now available including S. equi [90, 91] , S. pyogenes [92, 93] and Pasteurella multocida [94] . These information, combined with the advanced vectors developed for a wide number of hosting cell, allows the metabolic engineering of the HA pathway. Moreover, it is possible to transfer the HA synthesis capability from natural producer to non-producer hosting cells. Even though the metabolic engineering and genomic insertion for the improvement of HA production is possible in streptococci, the same result was easier achieved heterologus host microorganisms. Other advantages of heterologus HA synthesis reside in the exploitation of microorganism generally considered as safe for human health and the easier culture preparation and processing.
The enzymes involved in the HA pathway in streptococci are encoded in the bacterial genome as a monocistronic has operon. The has operon includes three genes: hasA that encodes for the HA synthetase [95] , hasB that encode for UDP-glucose dehydrogenase [96] and hasC that 558 Natural Product Communications Vol. 6 (4) 2011
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encodes for UDP-glucose pyrophosphorylase [97] . Heterologus expression of HA synthetatse (hasA gene in streptococci) in host bacteria such us Escherichia coli, Enterococcus faecalis or Bacillus subtilis, has shown to be sufficient to direct the production of HA [70, 98] . However, since HA and cell wall biosynthesis has partially common pathway (Figure 1 ), the depletion of sugar precursor caused by the high activity of HA synthetase would stop the cell from growing. To overcome this problem, at least a second gene hasB or its homologue must to be introduced at the same time [40, 98] .
Several microorganisms have been tried for the transformation into hosting cells for HA synthesis: Escherichia coli, Bacillus subtilis, Lactococcus lactis and Agrobacterium sp. The initial genetic modifications were performed on E. coli by the cloning and expression of the hasA gene from S. equi encoding for HA synthetase. However, the experiments demonstrated that, over expression of HA synthetase itself severely compromise the cells ability to growth [95] . More recently, a better result in the E. coli HA production was achieved by the coexpression of HA synthetase hasA gene (derived from P. multocida or S. pyogenes) respectively with hasB homologue (UDP-glucose dehydrogenase) or hasB + hasC homologues (UDP-glucose dehydrogenase + UDP-glucose pyrophosphorylase) from E. coli. The aim was to improve the intracellular availability of sugar precursor and prevent the inhibition of cell growing. The genes were organized into an artificial operon designed and constructed onto the backbone of proper plasmidic vectors. The HA yield was about 2 g/L but raised up to 3.8 g/L when the culture media was supplemented with glucosamine, suggesting close connection between energy metabolism and precursor supply. Even if the HA production was lower than the streptococci strains or others recombinant microorganisms, this work suggests suggest engineering routs to be exploited and the potential use of E. coli for industrial HA production [99, 100] .
Interesting was the works performed onto food grade microorganisms Agrobacterium sp. and Lactococcus lactis [101, 102] . Agrobacterium is already used in the production of curdlan for food applications and is generally considered as safe. In 2007, Mao and Chen, successfully transfered HA synthetase gene (hasA) from P. multocida and an UDP-glucose dehydrogenase homologue gene (hasB) from E. coli into Agrobacterium host. The coexpression of the two enzymes enables the host microorganism to produce HA up to 0.3 g/L. Even if the HA production yield was considerably lower than standard streptococci, the recombinant synthesis of HA in Agrobacterium specie was the first example of HA production into Gram-negative bacteria that naturally produce a food product [102] .
A similar result was obtained by Chien and Lee [101] on Lactococcus lactis, a food grade Gram-positive bacterium extensively used in the production of buttermilk and cheese. HA synthetase gene hasA from S. equi subsp. zooepidemicus was expressed alone or on combination with hasB gene (UDP-glucose dehydrogenase). The authors use a nisin-controlled expression vector (NICE) in order to separate the cell expansion from the HA production. When the desired rate cell density was reached, nisin was added to the culture to induce the expression of the foreign genes and finally, the HA production. The HA yield obtained was 0.08 g/L and 0.65 g/L respectively when HA synthetase (hasA) was expressed alone or in combination with UDP-glucose dehydrogenase (hasB). Even the production yield needs improvement, because the host microorganism is a foodgrade lactic acid bacteria, the HA production has high potential to applied in the field of food and biomedical industry [101] .
Novozymes obtained a successful result in the recombinant production of HA in Bacillus subtilis [103] [104] [105] . The microorganism is a well known non-pathogenic, Grampositive bacterium that was extensively studied and with a wide range of vector available that make it an obvious potential host for HA production. The authors produce a series of expression cassette containing the gene hasA (HA synthetase from S. equisiilis) alone or in combination with B. subtilis homologues of hasB (tuaD in Bacillus, encoding for UDP-glucose dehydrogenase), hasC (gtaB in Bacillus, encoding for UDP-glucose pyrophosphorylase), hasD (gcaD in Bacillus, encoding for Uridyltransferase/Nacetyltransferase bifunctional enzyme). The expression cassettes were cloned into appropriate vectors to construct artificial operons that were stable introduced into a specific locus of Bacillus subtilis host genome. The production yield obtained by the transformed Bacillus strain resulted to be comparable with the streptococci strains when hasA and tuaD genes were co-expressed by the artificial operon [104] . Interestingly, the overexpression of hasA alone does not seem to hinder the cell growth. Indeed, the authors report that, in contrast to E. coli, the Bacillus strain expressing HA synthetase alone resulted in HA production even if lower than others transformed strains. The HA production was dramatically improved by the coexpression of hasA and tuaD into the same operon. The meaning of the tuaD needing reside in the evidence that, endogenous tuaD gene is expressed only under phosphate starvation [55] . B. subtilis is inherently more metabolic robust than E. coli, at least regarding the HA synthesis, allowing a simultaneous support of both cell growing and HA synthesis [105] . In spite of no benefit in terms of HA yield and molecular weight compared to streptococci fermentation, recovery from B. subtilis is much easier because HA is not cell-associated and there is no contamination by streptococcal pathogenic factors [40] .
As an alternative to the prokaryotic HA production, it is possible to mention the HA synthesis occurring Chlorella cells, a unicellular green algae, when infected by Chlorovirus [106] . Experimentally, approximately 0.5-1 g/L of HA was recovered from infected Chlorella cells
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Finally, it is interesting the work of Takeo and colleagues [108] on the cloning and expression of mammalian HA synthetase. The authors genetically modify the genome of the fruit fly Drosophila melanogaster, a non-HAsynthesizing animal, by introduction of the single gene encoding mouse HA synthetase. The expression of HA synthetase in vivo resulted in massive HA accumulation in the extracellular space of the Drosophila tissues and caused various morphological defect. The original aim of the work was the development of an in vivo model to study the biosynthetic machinery of the polysaccharides besides, this could represent an alternative route for the HA production in eukaryotic cells [108] .
Chemical modification of hyaluronan
The interest in the role of hyaluronic acid in diseases such as various forms of cancers, arthritis and osteoporosis has led to new impetus in research and development. Our laboratory has been involved in the study of chemistry and physico-chemical properties of hyaluronic acid with a view to develop biomaterials and drugs conjugates [109] .
The repeating disaccharide unit, β-(1→4)-linked D-glucopyranuronic acid and β-(1→3)-linked 2-acetamido-2deoxy-D-glucopyranose, of hyaluronic acid contains two free hydroxyl groups at C-4,6 positions in the β-D-GlcpNAc moiety and in the β-D-GlcpA a carboxylic group at C-5' and two free hydroxyl groups at C-2',3' positions, as shown in Figure 2 . The chemical modifications on the hyaluronic acid backbone occur in these positions. In our laboratory, we have focused our research on regioselective modifications of the hydroxyl groups of HA. In particular, reactions at the 4-and 6-OH groups of the GlcNAc residues of the HA have led to a large number of well characterized derivatives. High-resolution NMR experiments have been used to determine the position and the degree of substitution and in some cases to study on a qualitative basis the effect of specific substitution on the conformation of the molecule. Molecular weight and molecular weight distribution determination, using High Performance Size Exclusion Chromatography (HP-SEC), has been performed to ascertain the molecular integrity of the reaction products. The low solubility of hyaluronic acid in organic solvents has been overcome by converting it into different organic counterions such as tetrabutylammonium, pyridinium and collidinium salts [110] . Such a derivatization imparts complete solubility in organic solvents and allows the chemical reaction to occur.
6-halodeoxy-hyaluronic acid:
Recently, HA was used as sodium salt without any derivatization in organic solvent (DMF) and in presence of methanesulfonyl chloride to generate regioselective 6-deoxy-6-chloro derivatives [111] . The reaction occurred in heterogeneous phase yielding halogenated HA derivatives suitable for further derivatization with drugs bearing nucleophilic groups. The complex methanesulfonyl chloride-DMF complex formed during the reaction permits selective replace of primary hydroxyl groups by chlorine [112] .
Alkyl and Aryl Esters derivatives of HA:
The carboxyl group of hyaluronic acid has been esterified by treatment with tetrabutylammonium salt in an aprotic solvent such as DMF or DMSO. Hyaluronic esters of ethyl, propyl, benzyl and dodecyl alcohols have been described as medical and pharmaceutical materials as medical sutures, films, microspheres, pellets, membranes, corneal shields and implants [113, 114] .
6-amino-6-deoxyhyaluronic acid:
The amino-deoxy derivatives of carbohydrates are of interest because they are components of biological materials such as glycoproteins and bacterial polysaccharides. They are usually synthesized by catalytic reduction of the corresponding azido derivatives, which in turn can be prepared from the corresponding halodeoxy compounds [115] . A direct, high yielding, synthesis of 6-amino-6deoxyhyaluronic acid has been achieved by selective amination of the C6-chlorinated HA in aqueous media under NH 3 pressure [116] .
Hyaluronic acid and methotrexate conjugate: Small molecule drugs such as antitumor compounds have been conjugated to synthetic and natural polymers. The advantages envisaged in this strategy are reduced toxicity, increased solubility and stability, localisation and controlled release of the drug. Methotrexate is used in the treatment of diseases such as inflammatory pathologies, autoimmune or neoplastic diseases. However, its therapeutic use is limited because of its high systemic toxicity. With a view to reduce the toxicity and enhance the efficacy of the drug, regioselective 6-O-methotrexylhyaluronic acid has been prepared by treatment of 6-chloro-6-deoxy HA with methotrexate in DMF [111] . Hyaluronic acid and taxol conjugate: Taxol (paclitaxel), an antileukemic and antitumor agent, was first isolated from the bark of the Pacific yew tree, Taxus bravifolia; has a limited solubility in water. Hyaluronic acid is over expressed at sites of tumor and provides a matrix to facilitate invasion. Hence, to overcome the solubility problem and to target the tumor cells, a first attempt to synthesize an hyaluronic acid conjugate of taxol was performed by Luo et al. by linking the taxol 2'-OH by way of succinate ester to adipic dihydrazide-modified HA (HA-ADH) [117] .
Recently, Lee et al conjugated paclitaxel and HA utilizing a novel solubilization method in a single organic phase. Hydrophilic HA was completely dissolved in anhydrous DMSO with addition of poly(ethylene glycol) (PEG) by forming nano-complexes. Paclitaxel was then chemically conjugated to HA in the DMSO phase via an ester linkage without modifying extremely hydrophilic HA [118] . The conjugate exhibited selective toxicity toward the human cancer cell lines (breast, colon and ovarian) that are known to express hyaluronic acid receptors; no toxicity was noted against a mouse fibroblast cell line at the same concentrations.
Hyaluronic acid and mitomycin C: Mitomycin C was linked to the HA molecule by way of an amide bond between the drug and the carboxyl group of the D-glucuronic acid moiety. An amide linkage formation is a dehydration reaction and requires anhydrous systems. However, as hyaluronic acid is difficult to dissolve in an anhydrous organic solvent, reaction conditions were developed to use a water based system [119] . Other strategies envisage the use of a succinylated HA as active intermediate for the conjugation with the drug [120] .
Hyaluronic acid and camptothecin conjugate: A novel methodology for making drug conjugates using hyaluronan as a carrier was recently developed. This strategy involves a completely regioselective two-step synthesis of 6-amino-6-deoxyhyaluronan, which is then easily functionalized making use of a simple succinate linker [116] .
Hyaluronic acid and other drugs:
A number of antitumor drugs, such as doxorubicin [121] and daunorubicin, have been linked at the amino function of the drug to the carboxylic group of an amino acid or a peptide spacer arm forming an amide linkage, and then through the terminal amino group of the amino acid or the peptide to the carboxyl group of the HA.
Hyaluronic acid and methylprednisolone:
Steroid-type of anti-inflammatory drugs such as methylprednisolone has proved to be efficacious in reducing symptoms associated with osteoarthritis of the knee [122] . Alkyl and aryl esters of HA have been used in the preparations containing methylprednisolone, both as polymer matrices in the form of microspheres wherein the drug is physically incorporated, and as substrates on which methylprednisiolone is chemically linked [123, 124] .
Hyaluronic acid and antioxidants: Reactive oxygen species (ROS) such as superoxide radicals generated by metabolic processes can depolymerise hyaluronic acid [125] . It has been demonstrated that many antiinflammatory drugs and free radical scavengers are efficacious in protecting hyaluronic acid depolymerisation by free radicals [126] [127] [128] .
Hyaluronic acid and propofol conjugate: 2,6-Diisopropylphenol (propofol) is an anaesthetic for intravenous administration whose efficacy as a free radical scavenger is due to its ability to form stable radicals. Its effectiveness as a scavenger for hydroxyl radicals generated by xanthine oxidase has been demonstrated by assessing in vitro the depolymerisation of hyaluronic acid in artificial synovial fluid [129] . Low-molecular-mass hyaluronic acid oligosaccharides have major biological effects: notably, they appear to play a role in the recruitment and activation of inflammatory macrophages, which may result in an exacerbation of the inflammatory process and tissue damage [130, 131] . For this reason, propofol was proposed as a shield for hyaluronic acid [124] .
Cross-linked Hyaluronic Acid-based materials:
Hyaluronic acid is rapidly metabolised in vivo by enzymes such as hyaluronidase [132] and by free radical oxidations [131] , which limit its use in native form as a biomaterial. In, addition hyaluronic acid is highly soluble in water. In order to overcome these limitations, the physico-chemical properties of hyaluronic acid have been modified using a variety of cross-linking reagents. These chemical modifications have led to a number of hyaluronic acid derivatives with a variety of physical formats such as liquids of various viscosities, fibers, weaves, sponges and fleeces. Cross-linked hyaluronic acids with special properties and structure, such as different degradation rate, different surface characteristics, different porosities, have applications as tissue engineering scaffolds for the delivery of cells, gene transfer, wound healing, post-surgical adhesion prevention, and implantation of bioactive compounds in vivo repair sites.
Ossipov et al. developed a new methodology exploiting a protective group strategy based on initial mild cleavage of a disulfide bond followed by elimination of the generated 2-thioethoxycarbonyl moiety ultimately affording free amine-type functionality. The strategy therefore encompasses a new approach for mild and highly controlled functionalization of HA with both nucleophilic and electrophilic chemoselective functionalities with the emphasis for the subsequent conjugation and in situ crosslinking [133] .
Li et al. synthesized a polymeric nanogel, with tumor targeting properties and a controllable phototoxicity, utilizing a low molecular weight-hyaluronic acid photosensitizer conjugate, resulting in the formulation of self-organizing nanogels in aqueous solutions [134] while Review on hyaluronan Natural Product Communications Vol. 6 (4) 2011 561
Kim et al synthesized hyaluronic acid/quantum dots (QDots) conjugates. The reaction was performed through amide bond between carboxyl groups of QDots and amine groups of adipic acid dihydrazide modified HA (HA-ADH) assessing the possibility of HA derivatives as target-specific drug delivery carriers for the treatment of liver diseases [135] . In the field of delivery systems alkylamino hydrazide hyaluronic acid (HA) derivatives were prepared to design new biocompatible films able to release hydrophobic drugs. These films were found to be more resistant to degradation by hyaluronidase compared to solutions of unmodified HA at the same concentration [136] . Bencherif et al developed a nanostructured hydrogel made of thiolated HA and reacted with biodegradable POEO 300 MA-co-PHEMA nanogels derivatized with acryloyl groups. The resulting scaffold was obtained through selective atom transfer radical polymerization (ATRP) and Michael-type addition reactions, affording a biocompatible matrix for cell and protein encapsulation in both tissue engineering and drug delivery applications [137] . Skoza et al exploited the specificity of hyaluronate lyase to biodegrade HA and introduce a double bond in the glucuronic acid moiety followed by the generation of free aldehyde group via ozonolysis and the subsequent reduction of the generated ozonide. This gives rise to a new reactive HA substrate to be derivatized with several molecules (such as biotin, polymers, or proteins) with application in tissue engineering and biomaterials production [138] .
A strong commercial interest drives the extensive use of HA hydrogels in cosmetics and tissue engineering. Due to the frequent use of HA derivatives in aesthetic surgery, novel, biocompatible, and non-toxic dermal fillers hyaluronic acid (HA) hydrogels were studied. Yeom et al successfully developed new hydrogel for tissue augmentation applications. Instead of using highly reactive cross-linkers such as divinylsulfone (DVS) [139] for Hylaform, 1,4-butanediol diglycidyl ether (BDDE) for Restylane, and 1,2,7,8-diepoxyoctane (DEO) for Puragen, HA hydrogels were prepared by direct amide bond formation between the carboxyl groups of HA and hexamethylenediamine (HMDA) with an optimized carboxyl group modification for effective tissue augmentation [140] . Crosslinked hyaluronic acid hydrogels have been specially designed and synthesized to promote tissue repair. A range of glycidyl methacrylate-hyaluronic acid (GMHA) conjugates have been synthesized and photopolymerized to lead to a number of crosslinked GMHA hydrogels with different physical properties such as swelling, mesh size. As expected, the amount of crosslinking and the degree of degradation was dependent on the amount of the conjugated methacrylate; the more crosslinking the less degradation rate [141, 142] . Su et al. developed an hydrogel formed by oxidated hyaluronic acid (oxi-HA) cross-linked with adipic acid dihydrazide (ADH). HA was oxidized by sodium periodate to create aldehyde functional groups, which could be cross-linked by ADH.
The result was a colorless, transparent and injectable hydrogel as potential vitreous substitute [143] . Other type of hydrogel were those made by Oldinsky et al, characterized by both a hydrogel and a hydrophobic polymer for biomedical applications. A series of amphiphilic graft copolymers consisting of HA, a glycosaminoglycan, and high-density polyethylene (HDPE), that is, HA-co-HDPE, were fabricated. Exploiting an esterification reaction between HA and functionalized HDPE the resulting material was a semicrystalline, insoluble powder applicable in saline suspension or molded form, including orthopedic tissue repair [144] .
The extreme versatility of HA is emphazised also by its employment in material science with carbon nanotubes. Hybrid hyaluronic acid (HA) hydrogels with single wall nanotubes (SWNTs) were formed by cross-linking with divinyl sulfone, producing considerable change in the morphology of the lyophilized hybrid hydrogels compared to HA hydrogels itself. As a final result, HA plays a dual role of matrix and linker for the rigid reinforcing nanofibers [145] . A similar approach was used by Mendes et al to produce hydrogels able to be used as potential biomaterials for the restoration of bone defects [146] .
Finally, a current cutting-edge topic is the development of biocompatible delivery systems to be used as a carrier for genetic material. Many attempts have been made to produce the -perfect‖ carrier, able to overcome all the issues related to the crossing of the biological barriers (enzyme degradation, endocytosis, intracellular trafficking), once administered in the body. Mok et al produced a Green covalently linked fluorescent protein (GFP) antisense oligodeoxynucleotide (ODN) / (HA) conjugate via a reducible disulfide linkage, and the HA-ODN was complexed with protamine to increase the extent of cellular uptake and enhance the gene inhibition efficiency of GFP expression [147, 148] . Furthermore, HA was derivatized exploiting the conjugation with polyethyleneimine (PEI) chains through the carboxylic groups to obtain a favorable positively charged environment for siRNA complexation [149] [150] [151] . This strategy could have potential applications as safe and effective nonviral carriers for ODN and siRNA nucleic acid therapeutics
Global markets and manufacturers
The use of hyaluronic acid (HA) has been extensively investigated in blends with other biopolymer and growth factors to form matrices to mimic the extracellular matrix surrounding the living cells. In this section commercially valuable application of hyaluronic acid as biomaterial will be described.
The HA market is led by several manufacturers who compete in different market segments related to their specific application. Seikagaku Corporation, manufacturing Artz HA viscosupplementant, is the largest company in the global HA market with its dominance in the Japanese market and its presence in Europe and US. Among the competitors, Seikagaku is followed by Genzyme Biosurgery. Q-Med dominates in the field of dermal filler while the largest competitor in the ophtalmic viscoelastics market is Advanced Medical Optics (AMO). Table 1 summarizes the composition of the main competitors in the field of HA-based biomaterials: An emerging company in the HA manufacturer's scenario is Novozymes, which has developed a patented process for production of HA form an bioengineered strain of Bacillus Subtilis. Also Anika Therapeutics recently strengthened its position market acquiring part of Fidia Advanced Biopolymers, producing hyaluronic acid-based products in several therapeutic areas including the regeneration of connective and structural tissues damaged by injuries, aging or degenerative diseases.
It is worth mentioning that in 2010 the global HA treatment market is foreseen to generate over $2 billion in revenues, demonstrating an overall compound annual growth rate (CAGR) in excess of 8%. The main sectors of extreme commercial interest are those related to:
-Dermal fillers -Ophtalmic viscoelastics -Viscosupplementation
In addition to these sectors other areas are being deeply investigated for their usefulness in commercial applications such as: -Tissue engineering -Adhesion barriers -Wound healing/wound dressing Dermal fillers: HA is one of the most used materials for dermal filler products. In fact, according to recent statistics, more than 85% of all dermal filler procedures occurred with a hyaluronic acid derivative [153, 154] . Dermal fillers for face rejuvenation were proposed on the market many years ago and received a large interest with the introduction of injectable bovine collagen. As the procedures for wrinkle correction with dermal fillers became more popular, the search began for safer, longer lasting fillers [155] [156] [157] . The next generation of filler after those made of bovine collagen was crosslinked hyaluronic acid derivatives, which was an improvement over bovine collagen in that it did not require a skin test for hypersensitivity and appeared to be longer lasting. The search for safer and more effective dermal fillers has continued because of the patients requirements to have fillers which predictably last longer than 6 months. In spite of a number of new temporary fillers composed of crosslinked hyaluronic acid that are available in Europe and are undergoing clinical testing in the United States, it is not fully understood what parameters control the performance of these fillers [158] . Nevertheless, the customer demand for such a products is very high and demonstrated by the list below, summarizing the most used crosslinked HA-based materials as dermal fillers ( Table 2) :
Several studies have been carried out to explain the properties [159] and the mechanism of action of dermal fillers. Wang et al. proposed that the injection of crosslinked hyaluronic acid stimulates collagen synthesis, partially restoring dermal matrix components damaged by environmental conditions (air, UV radiation). They hypothesize that this stimulatory effect may be induced by mechanical stretching of the dermis, which could activate the dermal fibroblasts. These findings suggest that crosslinked hyaluronic acid may be useful for stimulating collagen production therapeutically, particularly in atrophic skin conditions [160] . [140] . The research mentioned above indicates products which are under the spotlight of the cosmetic and pharmaceutic industries; the market segment of this type of products is mainly subdivided among the companies listed in Table 3 :
Ophthalmic viscoelastics: Hyaluronic acid is widely use in ophthalmology due to its viscosupplementant properties and its presence in the cornea, the sclera and the vitreous humor [165] . Ophthalmic viscoelastics are HA-based products used to maintain the structure of the eye's capsule, mainly in the phacoemulsification (removal of the eye's vitreous humor) step of cataract surgery [166] , but also in other surgical procedures such as vitreoretinal surgery, anterior segment surgery, glaucoma surgery, and corneal transplantation [167] . HA-based ophthalmic viscoelastics are used in every cataract procedure and intraocular lens implantation. Maintaining the eye's structural integrity without the fluid vitreous humor, viscoelastics also provide lubrification and protection to sensitive corneal tissue. Some studies have been carried out to produce a biocompatible materials for the vitreous humor replacement after vitrectomy using a new crosslinked HA through adipic acid dihydrazide bridges [143] and for cell sheet delivery applications [168] . By bonding to the fragments of the cloudy lens, viscoelastics act to facilitate natural lens removal toward the end of the phacoemulsification process. In this sector the main competitors are listed in Table 4 : Table 4 : Producers, products and relative market share of the manly used ophthalmic viscoelastics [152] . [169] .
Company
The use of these materials is also extended to the eye's cosmetic surgery. In fact, soft-tissue fillers have been successfully used for volume augmentation in the orbit, the tear trough, the upper eyelid/sub-brow region and in the brow and temple region. Non-animal stabilized hyaluronic acid fillers are the most commonly used in orbital and periorbital volume augmentation. As a matter of the fact, the role of injectable soft-tissue fillers in treating periorbital pathologies is gaining much interest, due to the results obtained in the treatment of paralytic lagophthalmos, lower eyelid retraction and cicatricial ectropion [170] .
Viscosupplementation: Intra-articular viscosupplementation was approved by the Food and Drug Administration (FDA) in 1997. HA viscosupplementation is a treatment for osteoarthritis (OA) sufferers where injectable, artificial produced HA supplements the body's own HA. The product acts to reduce joint pain while increasing joint mobility [171, 172] . The positive effects of HA are due in part to the fact that it influences physical properties, such as viscoelasticity and lubrification, and HA molecules interacts with the tissues in the joints. HA products are delivered as a series of injections and provide varying lengths of pain relief. It should be recognized that HA viscosupplementation doesn't cure osteoarthritis but rather serves as an intermediate treatment for patient who have not been successfully treated with pharmaceuticals [173] . The pain relief activity of this treatments is of course, not limited to OA itself but also to disease-related pain persistent after arthroscopic surgery [174] , such as meniscectomy or cartilage damage in joints.
Strauss et al. highlighted as intra-articular hyaluronic acid viscosupplementation was gaining popularity as a treatment option in the nonoperative management of patients with osteoarthritis. Recent clinical studies have demonstrated that the anti-inflammatory, anabolic, and chondroprotective actions of hyaluronic acid reduce pain and improve patient function. With evidence mounting in support of the efficacy of this treatment modality for patients with osteoarthritis, its potential use in patient populations affected by pathologies of weight-bearing joint such as knee [175] and ankles [176] is deeply investigated. Bencke et at. showed that the number of patients with osteoarthritis (OA) is expected to be growing. Viscosupplementation, in which hyaluronic acid is injected into the knee joint, has evolved into an important part of our current therapeutic regimen in addressing the patient with knee pain due to OA. Although suffering from lack of an "evidence-based" approach there is a growing body of data demonstrating the efficacy of HA in decreasing pain and improving function in patients with knee OA. The extensive use in clinic of HA has led to the introduction on the market of various forms of HA, although little data are available to justify one over the other [177] . Further proofs about the successful concept of HA as viscosupplementant were given by Mathieu et al during in vitro studies on rheological behavior of synovial fluids mixed with linear and crosslinked HA. They showed as in vitro tests highlighted the stability of HA over a period of 6 week without relevant alteration of the rheologic behavior and no pronounced degradation by catabolytic enzymes [178] . The pharmaceutical companies are very active in this field since these are high-demand products. The leading companies in the viscosupplementation field and the relative HA-based products are summarized in Table 5 . 
Tissue engineering:
The production of artificial 3D matrices is nowadays a challenging topic [179] , considering the in vitro tissue growth for surgical application a strong market need. Several approaches have been proposed to promote the cell growth on 3D-matrices made of biocompatible components. Due to a strong market demand for those kind of artificial tissues research in regenerative medicine is rapidly expanding to cope with this new need. Based on the concept of tissue regeneration triggered by HA-based materials, some products are commercially available for the treatment of deep dermal lesions such as non healing ulcers, deep II degree and III degree burns [180] (Hyalograft TM 3D), for autologous skin replacement (Laserskin®), for autologous fibroblasts and keratinocytes replacement (Tissuetech) and for wound healing/dressing, whose use will be discussed later on in this chapter.
In general, there is nowadays a trend towards supplying cells with a material to speed up the tissue healing process. Hydrogel encapsulation made of different biopolymers provides cells with a three dimensional environment similar to that experienced in vivo and therefore may allow the maintenance of normal cellular function in order to produce tissues similar to those found in the body [181] . Fan et al. synthesized galactosylated hyaluronic acid (GHA) prepared through the covalent coupling of lactobionic acid with HA. The derivative was then used to make highly porous three-dimensional sponges composed by a blend of chitosan and GHA. The mixture formed a 3D matrix stabilized by the electrostatic interaction between the two biopolymers. The matrix was applied to hepatocytes for liver-specific functions analysis. The addition of GHA not only improved the wettability and changed their mechanical properties, but also significantly influenced the cell attachment ratio. Moreover, liver functions of the hepatocytes entrapped in the CS/GHA scaffolds, such as albumin secretion, urea synthesis and ammonia elimination were improved in comparison with those in similar scaffolds made of chitosan [182] .
Kasahara et al. have developed an original threedimensional (3D) scaffold to meet improved biomechanical and biological requirements. The constructs were made of chitosan-based hyaluronic acid hybrid polymer fibers. Previous studies have shown that these hybrid polymer fibers have superior adhesion of chondrocytes and the ability to maintain chondrocyte phenotype. The study aimed at regenerating hyaline-like cartilage with sufficient mechanical properties combining a volume-reduced 3D scaffold and a bioreactor system. The implantation of such a biocomposites was proposed as a model approach for various cartilaginous lesions [183] .
Other studies, such that of Lee et al. focused on the fabrication of 3D highly porous scaffolds and their biochemical binding affinity to realize various biomimetic functionalizations. This was achieved by using a binding mechanism that incorporated molecules, which strongly bind to each other. A good example of such a binding molecule pair was avidin and biotin. In this work, a porous hybrid scaffolds composed of natural materials such as collagen and HA was prepared to evaluate morphology, mechanical strength, in vitro enzymatic degradation and cytotoxicity of the scaffolds as well as cell growth within the scaffolds [184] . Other attempts were proposed by Chou et al., who prepared a glue made of autologous fibrin as a potential scaffold with very good biocompatibility for neocartilage formation. However, fibrin glue has been reported not to provide enough mechanical strength, but with many growth factors to interfere the tissue growth. Gelatin/hyaluronic acid/chondroitin-6-sulfate (GHC6S) tricopolymer sponge was prepared as scaffold for cartilage tissue engineering and showed very good results in cell seeding and cell distribution [185] . The results indicated that the chondrocytes cultured in GHC6S-fibrin glue would effectively promote extracellular matrix secretion, inhibiting the degradation. The evidence could support that
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GHC6S-fibrin glue would be a promising scaffold for articular cartilage tissue engineering [186] . Hu and al reported the formation of biocompatible hydrogels using physically cross-linked biopolymers. Gellation of silk fibroin (from B. mori silkworm) aqueous solution was effected by ultrasonication and used to entrap blended, uncrosslinked, hyaluronic acid (HA) without chemical cross-linking. This is a novel approach to HA hydrogel systems, which otherwise require chemical crosslinking. Further, these systems exploit the beneficial material and biological properties of both polymers. These novel non-chemically cross-linked blend hydrogels may be useful for biomedical applications due to biocompatibility and the widespread utility of hydrogel systems [187] .
Adhesion barriers: Adhesions are a major cause of postsurgical morbidity and mortality and entail a substantial medical economic burden. It has been estimated that 90% of patients undergoing major abdominal surgery and 55% to 100% of women undergoing pelvic surgery develop adhesions. These phenomena are tightly linked to two risk factors: tissue injury and inflammation response. Clinically significant outcomes associated with adhesions include chronic pelvic and abdominal pain, bowel obstruction, and infertility. Consequently, methods for preventing such adhesions have been the focus of extensive research. Few barrier devices based on polysaccharides such as hyaluronic acid or oxidized regenerated cellulose are in commercial use, since part of them are based on synthetic polymers (polytetrafluoroethylene) [188, 189] . One of the most used adhesion barrier is Seprafilm®, a composite made of HA and carboxymethylcellulose employed in a wide range of applications such as in bowel obstruction in gynecological malignancies [190] , tendons repair [191] and after myomectomy, which is a procedure to surgically removed uterine fibroids from the uterus. This procedure often causes adhesion formation and decreases subsequent fertility. This was the reason to evaluate the effectiveness of several antiadhesion barrier materials in preventing adhesion after myomectomy. Tsuji et al. prospectively classified 63 women undergoing myomectomy alone into four groups according to the type of antiadhesion material used: Hyaluronic acid-carboxymethylcellulose film (Seprafilm ® ), Dextran 40 (10% Dextran 40 Low Injection ® ), factor 13 with fibrinogen (Beriplast ® ) and control. Seprafilm ® was highly effective and was superior to the other antiadhesion materials tested in preventing uterine adhesions after myomectomy [192] . Other HAbased product available on the market is INCERT ® -S (Anika), an anti-adhesion barrier gel for use in spinal surgeries such as discectomies with a laminectomy or laminotomy.
Other examples of dangerous adhesions are peritoneal adhesions. These are among the most frequent cases of tissue connections that form within the abdominopelvic cavity following surgery or other injuries. They can cause major medical complications. For this reason, researchers are combining barrier devices and pharmacological agents to be used in the prevention of this type of adhesion formation. It was hypothesized that an adhesion barrier, which also delivers anti-adhesion drugs, can address both physical and physiological causes for adhesion formation. For this reason an in situ cross-linking hyaluronan hydrogel (barrier device) was prepared containing the glucocorticoid receptor agonist budesonide [193] . A similar approach to prevent peritoneal adhesions was the application of physical barriers, which can separate the injured regions during peritoneal healing. The hybrid cross-linked HA-nanoparticles system appears to be a biocompatible and highly effective adhesion barrier. This -h ybrid system‖ is able to prevent postoperative peritoneal adhesions and combine the biocompatibility and ease of application of in situ cross-linkable hydrogels with the controlled release features of polymeric nanoparticles [194] . Furthermore, postoperative peritoneal adhesions can have serious, potentially lethal consequences. Pharmacotherapy and barrier devices can reduce adhesion formation to varying degrees, but their efficacy is limited by rapid clearance from the peritoneum and lack of biological activity, respectively. To overcome these limitations, Yeo et al. have delivered tissue-type plasminogen activator (tPA), which is deficient in the first 2-3 postoperative days, using a highly cross-linked in situ forming hyaluronan gel. They demonstrated this formulation's anti-adhesion activity in animal model that involved recurrent adhesions [193] . Bioresorbable membranes composed of hyaluronic acid and carboxymethylcellulose (HA/CMC) are the most effective method to prevent intra-abdominal adhesions; however, their efficacy may be limited to the site of application. Previous studies have shown that the intraperitoneal administration of a neurokinin-1 receptor antagonist (NK-1RA) reduces adhesions; however, the co-administration of HA/CMC plus an NK-1RA has not been studied. The co-administration of HA/CMC plus NK-1RA not only increases the efficacy of the membrane at the site of application, but also significantly reduces adhesions formation at distal unprotected sites. This combination may represent an emerging concept in more effective adhesion prevention throughout the peritoneum [195] . Zhao et al. prepared a sodium carboxymethylcellulose-Hyaluronic acid-Carboxymethylchitosan (CMCS) blend films. The results suggested that the material was held together by strong molecular interaction and hinted good compatibility in the blend films. The blend films are expected to be used as controllable degradation biomaterials in the field of postsurgical hemostasis and anti-adhesion [196] .
Wound healing and dressing: Successful repair of wounds and tissues remains a major healthcare and biomedical challenge in the 21st Century. In particular, chronic wounds often lead to loss of functional ability, increased pain and decreased quality of life. Advanced healing therapies employing biological dressings, skin substitutes, growth factor-based therapies and synthetic acellular matrices, all of which aim to correct irregular and 566 Natural Product Communications Vol. 6 (4) 2011 Murano et al. dysfunctional cellular pathways present in chronic wounds, are becoming more popular [197] . Commercially available HA-based products (for healing and dressing) on the market are Hyalofill-f, Hyalofill-R, Connettivina, Connettivina Plus, Jaloskin®, Hyalomatrix®. Hyalofill family products are absorbent, soft and conformable fibrous fleece (F) or rope (R) composed of HYAFF®, an ester of hyaluronic acid. Jaloskin® is a transparent film dressing for the treatment of superficial moderately exuding wounds. Hyalomatrix® is a bilayered, sterile, flexible, and conformable wound dressing that acts as an advanced wound care device.
HA uses in wound healing are strongly justified by its nonantigenic properties and the number of forms it can be manufactured, such as gels, creams to sheets of solid material through lightly woven meshes. Epidermal engraftment is superior to most of the available biotechnologies and, as such, the material shows great promise in both animal and clinical studies of tissue engineering. Ongoing research works focus on the ability of the biopolymer to enhance angiogenesis and the conversion of chronic wounds into acute wounds [198] . Moreover, Gao et al investigated the biological roles of hyaluronan (HA) fragments in angiogenesis acceleration. Studies have confirmed that oligosaccharides of HA (o-HA) are capable of stimulating neovascularization in vitro and promoting blood flow or angiogenesis in animal models. However, few laboratories have studied the function of o-HA as an exogenous treatment in injured tissue repair in vivo. It is thought that o-HA may lose its activities when used topically in vivo due to its small size, which may be absorbed quickly by the surrounding tissues. A special slow-releasing gel containing a mixture of o-HA at defined size was prepared and the healing effects, by topical application to an acute wound model, was studied. The therapy by o-HA was compared with high molecular weight HA and the known angiogenesis stimulator, VEGF, suggesting that o-HA therapy might be useful in acute wound repair [200] . Ferguson et al worked on HA fragments together to bioresponsive polymers to enhance the circulation time and stability of biologically active proteins and peptides, while reducing their immunogenicity and toxicity. Recently, crosslinked material made of HA at different molecular weights blended with arginine and epidermal growth factor (EGF) [201] and dextrin-EGF [202] conjugates were proposed, the latter exploiting the so called Polymer-masked UnMasked Protein Therapy (PUMPT) concept. The hypothesis is that conjugation of a biodegradable polymer to a protein would protect it and mask activity in transit, while enabling controlled reinstatement of activity at the target site by triggered degradation of the polymeric component. It has been developed and shown as potential modulators of impaired wound healing. In this contest, HA fragments (Mw 90,000 g/mol) were conjugated to trypsin as a model enzyme. HA-trypsin conjugates exhibited 52% greater stability in the presence of elastase, compared to free trypsin, demonstrating the potential use of HA conjugates as modulators of tissue repair. Ibrahim et al. showed that exogenous hyaluronic acid oligomers (o-HA) stimulate functional endothelialization, though native longchain HA was more bioinert and possibly more biocompatible. Additionally, the author created hydrogels containing high molecular weight HA (1 × 10 6 Da) and o-HA mixtures (HA-o: 0.75-10 kDa) crosslinked with divinylsulfone (DVS). The greatest endothelial cell (EC) attachment and proliferation was observed on gels with an high amount of o-HA. The study showed that the beneficial EC response to o-HA and biocompatibility of HA is mostly unaltered by their chemical derivatization and crosslinking into an hydrogel [203] .
